Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells

International Journal of Oncology

Volumn 38, Issue 2, 2011, Pages 555-569

  Dong, Yucui ^a   Jia, Limin ^a   Wang, Xiaohua ^a   Tan, Xiaoqing ^a   Xu, Jiankai ^a   Deng, Zhenling ^a   Jiang, Tao ^b   Rainov, Nikolai G ^c   Li, Baoxin ^a   Ren, Huan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c KLINIKUM AUGSBURG   (Germany)

Author keywords

Cell signaling pathways; Extracellular signal regulated kinase; Glioblastoma; Imatinib mesylate; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STAT3 PROTEIN;

ARTICLE; CANCER CELL; CELL CYCLE S PHASE; CELL FUNCTION; DRUG MECHANISM; ENZYME ACTIVATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GLIOMA; HUMANS; MICE; NIH 3T3 CELLS; PHOSPHORYLATION; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 78651255671     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2010.861     Document Type: Article

References (42)

1. Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med 359: 492-507, 2008.
2. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068, 2008.
3. Ren H, Yang BF and Rainov NG: Receptor tyrosine kinases as therapeutic targets in malignant glioma. Rev Recent Clin Trials 2: 87-101, 2007.
4. Omuro AM, Faivre S and Raymond E: Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 6: 1909-1919, 2007.
5. De Witt Hamer PC: Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro Oncol 12: 304-316, 2010.
6. Kesari S, Ramakrishna N, Sauvageot C, Stiles CD and Wen PY: Targeted molecular therapy of malignant gliomas. Curr Oncol Rep 8: 58-70, 2006.
7. Omuro AM: Exploring multi-targeting strategies for the treatment of gliomas. Curr Opin Investig Drugs 9: 1287-1295, 2008.
8. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B and Nistér M: Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52: 3213-3219, 1992.
9. Maxwell M, Naber SP, Wolfe HJ, Galanopoulos T, Hedley-Whyte ET, Black PM and Antoniades HN: Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J Clin Invest 86: 131-140, 1990.
10. Guha A, Dashner K, Black PM, Wagner JA and Stiles CD: Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer 60: 168-173, 1995.
11. Vassbotn FS, Andersson M, Westermark B, Heldin CH and Ostman A: Reversion of autocrine transformation by a dominant negative platelet-derived growth factor mutant. Mol Cell Biol 13: 4066-4076, 1993.
12. Kilic T, Alberta JA, Zdunek PR, et al: Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 60: 5143-5150, 2000.
13. Shamah SM, Stiles CD and Guha A: Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol Cell Biol 13: 7203-7212, 1993.
14. Druker BJ: Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91: 1-30, 2004.
15. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480, 2002.
16. Cools J, DeAngelo DJ, Gotlib J, et al: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201-1214, 2003.
17. Wen PY, Yung WK, Lamborn KR, et al: Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12: 4899-4907, 2006.
18. Reardon DA, Egorin MJ, Quinn JA, et al: Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23: 9359-9368, 2005.
19. Baruchel S, Sharp JR, Bartels U, et al: A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours. Eur J Cancer 45: 2352-2359, 2009.
20. Geoerger B, Morland B, Ndiaye A, et al: Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium. Eur J Cancer 45: 2342-2351, 2009.
21. Ren H, Tan X, Dong Y, Giese A, Chou TC, Rainov N and Yang B: Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells. Basic Clin Pharmacol Toxicol 104: 241-252, 2009.
22. Davies SP, Reddy H, Caivano M and Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105, 2000.
23. Demuth T, Hopf NJ, Kempski O, Sauner D, Herr M, Giese A and Perneczky A: Migratory activity of human glioma cell lines in vitro assessed by continuous single cell observation. Clin Exp Metastasis 18: 589-597, 2000.
24. Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P and Grant S: Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 62: 188-199, 2002.
25. Newton HB: Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways. Expert Rev Anticancer Ther 3: 595-614, 2003.
26. Stommel JM, Kimmelman AC, Ying H, et al: Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318: 287-290, 2007.
27. Roskoski R Jr: Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 356: 323-328, 2007.
28. Gross D, Bernhardt G and Buschauer A: Platelet-derived growth factor receptor independent proliferation of human glioblastoma cells: selective tyrosine kinase inhibitors lack antiproliferative activity. J Cancer Res Clin Oncol 132: 589-599, 2006.
29. Kwak EL, Clark JW and Chabner B: Targeted agents: the rules of combination. Clin Cancer Res 13: 5232-5237, 2007.
30. Hagerstrand D, Hesselager G, Achterberg S, et al: Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. Oncogene 25: 4913-4922, 2006.
31. Servidei T, Riccardi A, Sanguinetti M, Dominici C and Riccardi R: Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation. J Cell Physiol 208: 220-228, 2006.
32. Johnson FM, Saigal B and Donato NJ: Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. J Cell Physiol 205: 218-227, 2005.
33. + cells. Blood 103: 3167-3174, 2004.
34. Pandiella A, Carvajal-Vergara X, Tabera S, Mateo G, Gutierrez N and San Miguel JF: Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. Br J Haematol 123: 858-868, 2003.
35. Fabian MA, Biggs WH III, Treiber DK, et al: A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23: 329-336, 2005.
36. Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430, 2006.
37. Heymach JV: ZD6474-clinical experience to date. Br J Cancer 92 (Suppl 1): 14-20, 2005.
38. Sandstrom M, Johansson M, Andersson U, Bergh A, Bergenheim AT and Henriksson R: The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model. Br J Cancer 91: 1174-1180, 2004.
39. Brandes AA, Franceschi E, Tosoni A, Hegi ME and Stupp R: Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin Cancer Res 14: 957-960, 2008.
40. Wen PY and Kesari S: Malignant gliomas. Curr Neurol Neurosci Rep 4: 218-227, 2004.
41. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG and Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239, 2009.
42. Ziegler DS, Wright RD, Kesari S, et al: Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. J Clin Invest 118: 3109-3122, 2008.